Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.
FERRLECIT has been shown to improve anemia outcomes in chronic hemodialysis patients receiving supplemental erythropoietin therapy. In an open-label, multicenter, randomized comparative study, FERRLECIT produced a mean increase in hemoglobin of 1.0 g/dL 2 days after completion of a 1-gram course of therapy administered over 8 sequential dialysis sessions.
